New directions in the management of advanced pancreatic cancer: a review

Anti-cancer Drugs
Caio M Rocha-Lima

Abstract

Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time of diagnosis, or will relapse after surgery. Systemic chemotherapy is only palliative. Gemcitabine-based therapy is an acceptable standard for unresectable locally advanced/metastatic pancreatic cancer, but average median survival is only 6 months. The addition of other chemotherapies (including other antimetabolites, platinum, and topoisomerase I inhibitors) or targeted therapies (farnesyl transferase inhibitors, metalloproteinase inhibitors, cetuximab and bevacizumab) to gemcitabine has failed to improve outcome. The combination of gemcitabine and erlotinib, a small-molecule tyrosine kinase inhibitor of the human epidermal growth factor receptor, was recently approved by the US/European authorities for use in advanced disease. In a phase III trial, the combination demonstrated a significant improvement in overall survival compared with gemcitabine monotherapy. Positive efficacy results have also been observed in a phase III trial, favoring the addition of capecitabine to gemcitabine compared with gemcitabine alone. This review focuses on the recent developments in syste...Continue Reading

References

Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R GrunewaldW Plunkett
Mar 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L AbbruzzeseM N Raber
Mar 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·T KawamotoJ Mendelsohn
Jul 1, 1995·Critical Reviews in Oncology/hematology·D S SalomonN Normanno
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K FujimotoM Imamura
Jun 9, 1999·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·D BirkH G Beger
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S R BramhallUNKNOWN Marimastat Pancreatic Cancer Study Group
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R I NicholsonM E Harper
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas H CartwrightJoseph J Schulz
Jan 5, 2002·Annals of Surgical Oncology·R R WhiteD S Tyler
Jun 18, 2002·Seminars in Oncology·Peter Naredi
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jordan D BerlinAl Bowen Benson
Nov 8, 2002·Seminars in Oncology·Henry Q Xiong, James L Abbruzzese
Feb 27, 2003·Critical Reviews in Oncology/hematology·Ian ChauDavid Cunningham
May 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiro FukuokaJosé Baselga
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaret TemperoJames Abbruzzese
Aug 9, 2003·Seminars in Oncology·James Y TsaiHoward Safran
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G P StathopoulosV Georgoulias
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vincent A MillerRobert T Heelan
Mar 19, 2004·The New England Journal of Medicine·John P NeoptolemosUNKNOWN European Study Group for Pancreatic Cancer
Mar 31, 2004·Lancet·Donghui LiJames L Abbruzzese
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David R GandaraWilbur A Franklin
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Giorgio V ScagliottiFred R Hirsch
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry Q XiongJames L Abbruzzese
Aug 5, 2004·Journal of the National Cancer Institute·Federico CappuzzoLucio Crinò
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio M Rocha LimaLangdon L Miller
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetUNKNOWN GISCAD

❮ Previous
Next ❯

Citations

Mar 27, 2010·Cancer Chemotherapy and Pharmacology·Nicholas O RomanRobert T Dorr
Apr 21, 2010·International Journal of Colorectal Disease·Dietrich SturmJoerg Emmrich
Sep 15, 2010·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Mukund S DidolkarStuart Rabinowitz
Dec 3, 2013·Indian Journal of Surgical Oncology·Vasiliki Th KaragianniJohn K Triantafillidis
Jul 16, 2010·Nature Reviews. Gastroenterology & Hepatology·Ruchika GuttRalph R Weichselbaum
Apr 12, 2011·Folia Histochemica Et Cytobiologica·Anil Kumar AgrawalMaciej Siewiński
Mar 31, 2011·World Journal of Gastroenterology : WJG·Tobias HeyeLars Grenacher
Feb 23, 2013·World Journal of Gastroenterology : WJG·Ioannis KoutsounasStamatios Theocharis
Mar 14, 2013·World Journal of Gastroenterology : WJG·Ioannis KoutsounasStamatios Theocharis
Apr 11, 2014·Journal of Clinical Gastroenterology·Edmée C M SikkensMarco J Bruno
Oct 15, 2008·Expert Opinion on Therapeutic Targets·Devalingam Mahalingam, Francis Giles
Sep 1, 2009·Expert Review of Clinical Pharmacology·Jia LiMuhammad W Saif
May 27, 2009·Expert Opinion on Emerging Drugs·Devalingam MahalingamFrancis J Giles
Dec 6, 2011·Cancer Letters·Si ShiXianjun Yu
Feb 17, 2009·Seminars in Oncology Nursing·Carmel SauerlandDavid B Pearlstone
Nov 13, 2009·International Journal of Cancer. Journal International Du Cancer·Kuzhuvelil B HarikumarBharat B Aggarwal
Jun 17, 2011·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Pascale Cervera, Jean-François Fléjou
Jan 11, 2018·Journal of Magnetic Resonance Imaging : JMRI·Chao LiuChengli Li
Apr 4, 2015·World Journal of Gastroenterology : WJG·Chiang J TyngRubens Chojniak
Jun 16, 2015·World Journal of Gastroenterology : WJG·Ya-Bin YuDian-Hua Gu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.